Drug Profile
Azvudine - Zhengzhou Granlen PharmaTech
Alternative Names: FNC; Jie Bei AnLatest Information Update: 03 Mar 2023
Price :
$50
*
At a glance
- Originator Zhengzhou University
- Developer HeNan Sincere Biotech Co. Ltd; Shanghai Henlius Biotech; Zhengzhou Granlen PharmaTech
- Class Antiretrovirals; Antivirals; Azides; Fluorinated hydrocarbons; Pyrimidinones; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered COVID-19 pneumonia; HIV infections
- Phase III COVID 2019 infections
Most Recent Events
- 06 Jan 2023 Phase-II clinical trials in COVID-2019 infections (In volunteers, Prevention, In adults, In the elderly) in China (PO) (NCT05682599)
- 29 Dec 2022 Phase-II/III clinical trials in COVID-2019 infections (Prevention) in Philippines (PO) (NCT05633433)
- 01 Dec 2022 Shanghai Henlius Biotech in collaboration with Shanghai Fosun Pharmaceutical and HeNan Sincere Biotech plans a phase II/III trial in COVID-2019 infections(In volunteers, Prevention) in Malaysia and Philippines(PO) in December 2022(NCT05633433)